Fig. S1.

Steady state plasma exposure of pexidartinib in patients receiving 1000 mg daily on a BID (uneven split dose) regimen.
Depicted are the AUC_{0-4hr} available for 78 patients from 5 disease-specific cohorts (2 MECs, 36 TGCTs, 10 GISTs, 7 ATCs, and 5 malignant effusions) and 1 miscellaneous tumor cohort (18). The horizontal bar indicates the geometric mean AUC_{0-4hr} for each cohort. The geometric mean AUC_{0-4hr} for all 78 patients is 26,052 ng·hr/mL (range 10,201 ng·hr/mL to 54,206 ng·hr/mL). The geometric mean AUC_{0-4hr} for the 36 patients with TGCT is slightly lower, 23,581 ng·hr/mL (range, 13,374 ng·hr/mL to 43,778 ng·hr/mL), but the difference is not statistically significant.

ATC = anaplastic thyroid carcinoma; AUC = area under the curve; BID = twice per day; GIST = gastrointestinal stromal tumor; MEC = mucoepidermal carcinoma; TGCT = tenosynovial giant cell tumor.